Arca Biopharma Inc (NASDAQ:ABIO) recently announced that Chicago’s American Heart Association Scientific Sessions selected its Atrial Fibrillation Burden (AFB) substudy for the Phase 2B GENETIC-AF clinical trial for a poster presentation. The sessions will take place between November 10 and 12, 2018. Arca is a biopharmaceutical company that applies an accurate medicine approach to develop cardiovascular disease-related genetically-targeted therapies. On behalf of the company, Duke University Medical Center’s Associate Professor of Medicine as well as Director of the Duke Center for Atrial Fibrillation, Jonathan Piccini will make the presentation at the Chicago session.
Phase 2B clinical trial presentation report spikes ABIO shares
Immediately after the announcement by ABIO about AHASS picking up its Phase 2B clinical trial data for presentation at the large Chicago’s healthcare conference, the shares of the company spiked and made its way into the green. Reports indicate that ABIO started off strongly in the pre-market early morning hours after the announcement of upcoming presentation.
The press release from ABIO stated that the presentation titled, “Phase II Trial of Pharmacogenetic Guided Beta-Blocker Therapy with Bucindolol vs. Metoprolol for the Prevention of Atrial Fibrillation/Flutter in Heart Failure: Genetic-Af Af Burden Substudy” will be available from November 11, 2018 onwards. The market trend shows that the news about the presentation worked overwhelmingly positively for the company.
It is mostly because the company is presenting its study report at a highly trusted event in the field of medicine in front of some of the biggest investors, key figures as well as partners. Also, acceptance of ABIO’s Phase II trial study data will instigate more confidence in the team of the company working against Atrial Fibrillation in patients with heart failure. That is one reason for the excitement among the investors and is pushing the ABIO stock in the upward direction in the stock market.
Things to watch ahead
Analysts are keeping a close eye on ABIO’s activity and continued work related to introducing new options for patients with Atrial Fibrillation. The presentation of data is sure to create a major ripple for the company in the stock market.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.